Exon Science, Biotech VC Trends and PhRMA’s Next CEO | The Readout LOUD Podcast

• Exon-skipping science, particularly in the context of Duchenne muscular dystrophy, is gaining renewed clinical traction despite being an established methodology.
• Biotech venture capital firms are facing systemic strain driven by the disruptive integration of artificial intelligence and geopolitical tensions involving China.
• Despite recent record-breaking fundraising cycles, the “playbook” for biotech investment is being rewritten as firms scramble to adapt to fresh regulatory and technological pressures.

The current clinical landscape is marked by a return to foundational genetic strategies. The renewed interest in exon science—specifically the mechanism of exon skipping to treat Duchenne muscular dystrophy—highlights a critical shift in how researchers approach protein restoration. By bypassing specific mutations in the genetic code, clinicians aim to produce a shorter but still functional version of the dystrophin protein, thereby reducing the morbidity associated with the disease. This is not a “miracle cure,” but rather a targeted refinement of existing science that addresses a persistent clinical gap in neuromuscular care. For families and patients navigating the complexities of genetic mutations, the path to treatment requires precise diagnostic mapping. It is essential to consult with board-certified neurologists who specialize in neuromuscular disorders to determine if these evolving exon-skipping therapies are appropriate for a specific genetic profile. The resurgence of this science occurs against a backdrop of extreme financial instability within the biotech funding ecosystem. The venture capital landscape, which saw record-breaking activity between 2024 and 2025, is now exhibiting signs of severe friction. The scale of previous investments was immense, with firms like Flagship raising $3.6 billion and ARCH raising over $3 billion. Similarly, Bain Capital Life Sciences secured $3 billion, while Vida Ventures achieved a staggering $8 billion in exits in a single year. However, these figures mask a growing anxiety among investors.

“Why is old exon science getting new traction? What’s unsettling biotech VCs?”

This question, central to the current discourse in the industry, points to a “scrambled playbook.” The traditional model of funding—identifying a promising molecule, scaling through clinical trials, and exiting via an IPO or acquisition—is being disrupted. Two primary catalysts are driving this instability: the rapid ascent of artificial intelligence and the complexities of operating within the Chinese market. Artificial intelligence is no longer just a tool for drug discovery; it is fundamentally altering the valuation of biotech firms. AI’s ability to accelerate lead optimization and predict toxicity is straining traditional VC firms that lack the technical infrastructure to vet AI-driven claims. Simultaneously, geopolitical tensions and regulatory shifts involving China are creating operational bottlenecks for firms with global portfolios. This environment of uncertainty necessitates a rigorous audit of international partnerships and intellectual property protections. Pharmaceutical entities and investment firms are increasingly relying on healthcare compliance attorneys to navigate the legal minefields created by these shifting international relations. The instability extends to the highest levels of industry advocacy. The ongoing search for the next CEO of PhRMA signals a leadership transition at a time when the industry must reconcile its pricing models with the arrival of highly disruptive, AI-integrated therapies. The transition in leadership reflects a broader require for a strategy that can withstand both political scrutiny and the volatility of the biotech market. The financial disparity between the “winners” and the “strugglers” is becoming more pronounced. While New Enterprise Associates (NEA) continues to leverage its deep networks in Silicon Valley to support both early and late-stage healthcare disruptions, other firms are finding that their previous success in M&A (mergers and acquisitions) is not a guaranteed roadmap for the future. The transition from a period of record fundraising to one of “unsettled” investment suggests that the cost of capital is rising, and the tolerance for scientific risk is narrowing. For startups and established biotech firms attempting to pivot their strategies in this climate, the need for operational agility is paramount. Navigating this “scrambled playbook” requires more than just capital; it requires a strategic alignment of clinical goals and market realities. Many firms are now engaging specialized biotech consultants to restructure their portfolios and ensure their scientific milestones align with the current risk appetite of investors. The trajectory of biotech innovation is rarely linear. The current revival of exon science proves that “old” science can provide new solutions when refined by modern clinical insights. However, the sustainability of these breakthroughs depends entirely on the stability of the funding mechanisms. If the venture capital community cannot resolve the strains imposed by AI and geopolitical instability, the gap between laboratory discovery and bedside application may widen. The industry is moving toward a model where scientific validity must be paired with extreme regulatory and financial transparency. As we move further into 2026, the focus will likely shift from the volume of capital raised to the efficiency of that capital’s application. The goal remains the reduction of patient morbidity through precise, evidence-based interventions, regardless of the volatility in the boardroom. *Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*